IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
February 22, 2024 08:00 ET
|
Imunon, Inc.
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
IMUNON Reports 2022 Financial Results and Provides Business Update
March 30, 2023 08:00 ET
|
Imunon, Inc.
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused...
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
July 27, 2020 08:30 ET
|
Celsion CORP
Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for...